KNIGHT THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.79 CAD | -1.19% |
|
-1.36% | +11.56% |
| Mar. 22 | Knight Therapeutics Price Target Raised to $7 at RBC | MT |
| Mar. 21 | Knight Therapeutics Reports Fourth Quarter Results | MT |
Presentation Operator MessageOperator (Operator)Welcome to Knight Therapeutics, Inc. Fourth Qu...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.79
CAD
Average target price
6.729
CAD
Spread / Average Target
+16.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.56% | 426M | |
| +10.08% | 9.12B | |
| -15.94% | 4.8B | |
| +18.47% | 3.72B | |
| +1.89% | 3.8B | |
| +26.41% | 2.58B | |
| -24.63% | 2.36B | |
| -29.37% | 2.11B | |
| +2.55% | 1.86B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Transcript : Knight Therapeutics Inc., Q4 2021 Earnings Call, Mar 24, 2022
